Introduction to relevant information about the trametinib targeted drug MEK1/2

Trametinib is a highly selective inhibitor of MEK1 and MEK2. It is a MAPK pathway inhibitor drug and plays an important role in molecular targeted therapy. MEK1/2 is a core member of the Ras-Raf-MEK-ERK signaling pathway, which is abnormally activated in a variety of tumors, especially tumor types carrying RAS or BRAF mutations, such as melanoma, non-small cell lung cancer (NSCLC), thyroid cancer, etc. Trametinib blocks the activity of MEK kinase, thereby preventing the continued proliferation and survival signals of tumor cells, providing precise targeting for tumor treatment.

At present, trametinib has been approved for multiple indications worldwide, the most clear of which is the combination with the BRAF inhibitor dabrafenib for the treatment of melanoma with BRAF V600E or V600K mutations. This combination regimen not only improved progression-free survival, but also significantly reduced the tumor recurrence rate. In addition to melanoma, trametinib is also being explored in multiple clinical studies for the treatment of other solid tumors carrying BRAF or RAS mutations, including thyroid cancer, low-grade glioma, biliary tract cancer, and non-small cell lung cancer. In certain refractory lung cancer subtypes, the combination of trametinib and dabrafenib has shown good response rates, especially in patients with BRAF V600E mutation-positive patients, and has become a new clinical direction.

From a pharmacological perspective, trametinib has high selectivity and can reduce the impact on normal tissues. Its half-life is approximately4-5 days, which supports once-daily oral administration and improves patient compliance. In China, the drug has completed marketing approval, and the original drug is available to ensure the consistency and safety of treatment. As a representative drug of the MEK pathway, trametinib can not only be used as a single drug, but also suitable for combination strategies with other targeted or immune drugs. It is an important tool to achieve personalized treatment of tumors. With the deepening of research on the MAPK signaling pathway, MEK inhibitors have shown promise in regulating multiple drug resistance mechanisms, remodeling the microenvironment, and combined immunotherapy.

Reference materials:https://go.drugbank.com/drugs/DB08911